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Thrombomodulin (TM) is an important vascular protective molecule that has anticoagulant, anti-
inﬂammatory and anti-apoptotic properties. TM is downregulated in many thrombotic and vascular
diseases. However, the mechanisms responsible for TM suppression are not completely understood.
In this study, we investigated the mechanism involved in fatty acid-induced suppression of TM
expression in human aortic endothelial cells. We found that palmitic acid inhibited TM expression
through the JNK and p38 pathways. ATF-2, a JNK and p38 target transcription factor, was involved in
the suppression. ATF-2 can bind to the TM promoter, recruit HDAC4 and form a transcriptional
repression complex in the promoter, which may lead to chromatin condensation and transcrip-
tional arrest. This study provides novel insight into TM down-regulation by stress signaling path-
ways.
Structured summary:
MINT-7555703, MINT-7555712: HDAC4 (uniprotkb:P56524) physically interacts (MI:0915) with ATF-2
(uniprotkb:P15336) by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction agulation. Mutation or down-regulation of TM promotes [8,9],Endothelium plays an active role in regulating pro-coagulation
and anti-coagulation balance by generating several active regula-
torymolecules, such as vonWillebrand factor (vWF), thrombomod-
ulin (TM), tissue plasminogen activator (t-PA), and plasminogen
activator inhibitor (PAI-1) [1,2]. Among these factors, TM-protein
C pathway is a major physiological anticoagulation system of the
endothelium [3]. Endothelial dysfunction can cause coagulation
dysregulation and promote vascular thrombosis.
TM, a glycoprotein on the surface of endothelial cells, is a key
factor in protein C activation [3]. When bound to thrombin, TM
triggers the activation of protein C by facilitating the conversion
of circulating protein C to activated protein C (APC). APC can inhibit
coagulation by degrading VIIIa [4] and factor Va [4–6] and enhance
ﬁbrinolysis by inactivating PAI-1 [7]. TM plays a key role in antico-chemical Societies. Published by E
Cardiothoracic Surgery, The
ouston, TX 77030, USA.
hyshen@bcm.edu (Y.H. Shen).while overexpression of TM prevents [10] arterial thrombosis. In
addition, TM functions as an anti-inﬂammatory and anti-apoptotic
molecule. It has been shown that TM inhibits inﬂammatory re-
sponse [11–14] and blocks cell apoptosis [15–17]. TM is down-reg-
ulated in vascular diseases including atherosclerosis [18], and TM
is negatively regulated by inﬂammatory factors [19–21], wall ten-
sion [22,23] and oxidized lipids [24–26]. However, the mecha-
nisms involved in the down-regulation of TM expression are not
completely understood.
Stress signaling JNK and p38 pathways are activated in many
cardiovascular diseases including atherosclerosis and are involved
in pathophysiological changes in these conditions [27,28]. JNK and
p38 signaling pathways are activated by metabolic stress [29]
and inﬂammatory factors [30,31]. We previously showed that
JNK and p38 can be activated by free fatty acids (FFA) and were
involved in vascular insulin resistance [29], it is interesting to
know whether activation of these pathways by FFAs also affects
TM expression.
In this study, we examined the effects of activation of JNK and
p38 by FFAs on TM regulation and investigated the mechanisms
involved.lsevier B.V. All rights reserved.
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2.1. Cell culture
Human aortic endothelial cells (HAECs) (Cell Applications, San
Diego, CA) were grown in endothelial cell basic medium (EBM)
containing 2% FBS, FGF-2, VEGF, IGF-1, EGF, ascorbic acid, GA-
1000, hydrocortisone, and heparin. HAECs, of 5–9 passages, were
plated on six-well plates, and then treated with palmitic acid or
transfected with siRNAs.
2.2. Preparation of fat acid–albumin complexes
HAECs were treated with 0.5% BSA alone or different concentra-
tions of saturated palmitic acid (PA, also known as hexadecanoic
acid) for 24 h. Preparation of PA was carried out as previously
[29]. Brieﬂy, PA was dissolved in ethanol at 200 mM, and then
combined with 10% FFA-free low endotoxin BSA to ﬁnal concentra-
tions of 1–5 mM. The pH of all solutions was adjusted to approxi-
mately 7.5, and the stock solutions were stored at 20 C. Control
solution containing ethanol and BSA was prepared similarly. Work-
ing solutions were prepared fresh by diluting stock solution (1:10)
in 2% FCS-EBM. The ﬁnal 1% BSA was consistent in all FFA medium,
whereas the FFA/BSA ratio varied with the FFA concentrations.
2.3. siRNA transfection
Negative control siRNA or speciﬁc p38 siRNA, JNK siRNA and
ATF-2 siRNA were purchased from Ambion (Austin, TX). HAECs
were transfected with negative control or speciﬁc siRNAs using
Lipofectamine2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Transfected cells were treated with
palmitic acid for 24 h.
2.4. Western blotting
Cell lysate from treated HAECs were prepared as described pre-
viously [29,31]. Protein concentration was measured using a
Bio-Rad Protein Assay Reagent kit (Bio-Rad, Hercules, CA). The cell
lysates were subjected to SDS–polyacrylamide gel electrophoresis
and transferred to PVDF membranes. The membranes were
blocked, incubated overnight with primary antibody, washed,
and then incubated with the secondary horseradish peroxidase-la-
beled antibody. Signal detection was performed with enhanced
chemiluminescence (Amersham Biosciences, Piscataway, NJ). The
data shown was representative of three separate experiments.
2.5. RNA extraction and real-time quantitative PCR
Total RNA was extracted from HAECs with Trizol (Invitrogen).
Signal-strand cDNA was synthesized with iScript cDNA synthesis
kit (Bio-Rad). Semi-quantitative real-time PCR was performed with
iCycler iQ real-time PCR detection system (Bio-Rad). The primers
for human TM mRNA were as follows: forward: 50-CCGATGTC
ATTTCCTTGCTA-30; reverse: 50-GTTGTCTCCCGTAACCCACT-30. The
mRNA levels were acquired from the value of the threshold cycle
(Ct) of TM normalized against the Ct of b-actin.
2.6. Chromatin immunoprecipitation assay
The ChIP assay kit (Upstate) was used as previously described
[29,31]. In brief, treated HAECs were ﬁrst incubated with 1% form-
aldehyde at 37 C for 15 min to cross-link DNA–protein complexes.
Cells were then rinsed and lysed. Cell lysates were sonicated and
centrifuged to produce chromatin fragments. The supernatantswere pre-cleared with a mixture of salmon sperm DNA/protein
A/protein G, followed by immunoprecipitation with antibody-pro-
tein A-agarose slurry (IgG served as the negative control). The
immunocomplex beads were then washed sequentially with low
salt-wash buffer, high salt-wash buffer, LiCl wash buffer, and TE
buffer. The immunocomplex was eluted with elution buffer. The
eluted immunocomplex and the inputs were incubated with
200 mM NaCl at 65 C overnight to reverse the cross-link, and then
incubated with proteinase K to digest the remaining proteins. The
DNA was recovered by extraction with the phenol/chloroform/iso-
amyl alcohol mixture. The immunoprecipitated DNA was used as a
template for PCR. The PCR products were separated by 1.5% aga-
rose gel. The primers used for the AP-1 binding site in the 50-ﬂank-
ing region of the human TM gene were: forward primer 50-TAAA
CAGTTTGCCTCTCACC-30 and reverse primer 50-TCCTGTGGATGGG
CAGGGTG-30.
2.7. Immunoprecipitation
Immunoprecipitation was conducted as described previously
[32,33].Treated cells were lysed for 60 min in ice-cold extraction
buffer containing 50 mM Tris–Cl (pH 7.5), 100 mM NaCl, 1% Triton
X-100, 1 mMdithiothreitol, 1 mMEDTA, 1 mMEGTA, 2 mMNa3VO4,
50 mM b-glycerophosphate, and a protease inhibitor mixture
(Amersham Biosciences). For immunoprecipitation, cleared cell ly-
sates were incubated with the appropriate antibody precoupled to
protein A/G-agarose beads (Santa Cruz Biotechnology) at 4 C over-
night. Thebeadswerewashed twicewithextractionbuffer andtwice
withextractionbuffer containing0.5 MLiCl. Proteinswereeluteddi-
rectly in SDS sample buffer for Western blot analysis.
2.8. Statistical analysis
Data are presented asmean ± S.E.M. of three independent exper-
iments. One-wayANOVAwasused to analyze thedifferences among
groups. P values <0.05 were considered statistically signiﬁcant.3. Results
3.1. Free fatty acids suppressed TM expression in HAECs
We ﬁrst examined whether palmitic acid (PA) regulated the
expression of TM in HAECs. HAECs were incubated with different
concentrations of PA for 24 h. Western blotting showed that PA sig-
niﬁcantly suppressed the expression of TM in a dose-dependent
manner (Fig. 1A). Furthermore, PA signiﬁcantly inhibited the
expression of TM mRNA (Fig. 1B), indicating that PA may suppress
TM expression at the transcriptional level.
3.2. JNK and p38 stress pathways were involved in PA’s inhibitory
effect on TM expression
We next determined whether JNK and p38 pathways were in-
volved in PA’s inhibition of TM expression. The activation of these
two pathways was examined. Consistent with previous observa-
tion [29], JNK and p38 were activated by PA in a dose-dependent
manner (Fig. 2A). Importantly, silencing JNK and p38 with speciﬁc
siRNAs reversed PA-induced TM suppression (Fig. 2B), indicating
that JNK and p38 pathways mediated PA-induced inhibition of
TM expression.
3.3. ATF-2 was involved in JNK and p38-mediated TM suppression
We further studied the mechanisms by which JNK and p38
mediated PA-induced down-regulation of TM mRNA. JNK and
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Fig. 1. Palmitic acid (PA) inhibited thrombomodulin (TM) expression in human aortic endothelial cells (HAECs). HAECs were treated with different concentrations of PA for
24 h. (A) TM protein expression was examined by Western bolt using anti-TM antibody. The relative levels of protein were compared and expressed as percentages of the
control. Representative blots and quantitative analyses from three independent experiments are shown. ***P < 0.001 versus the no-treatment control. (B) Relative TM mRNA
was analyzed by RT-PCR and normalized with b-actin mRNA. The relative levels of mRNA were compared and expressed as the percentage of the control. Results are
expressed as means ± S.E.M. (n = 3). **P < 0.01, ***P < 0.001 versus no PA control.
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Fig. 2. JNK and p38 pathways mediated PA’s inhibitory effect on TM expression. (A) Activation of JNK and p38 by PA. HAECs were treated with different concentrations of PA
for 24 h. The phosphor-JNK and total-JNK as well as phosphor-p38 and total-p38 were detected by Western blot. (B) JNK and p38 pathways mediated PA’s inhibitory effect on
TM expression. HAECs were transfected with negative control siRNA, or JNK siRNA or p38 siRNA followed by incubation with PA for 24 h. TM expression was examined by
Western blot. The relative levels of protein were compared and expressed as percentages of the control. Representative blots and quantitative analyses from three
independent experiments are shown. *P < 0.05, **P < 0.01, ***P < 0.001 versus the no-treatment control, or as indicated.
854 Y. Rong et al. / FEBS Letters 584 (2010) 852–858p38 are involved in gene regulation by activating an array of tran-
scriptional factors. The most important target transcriptional fac-
tors are activating protein-1 (AP-1), a group of transcription
factors including Jun, Fos, ATF and Maf. We have previously shown
that PA can activate ATF-2, which mediates p38-induced upregula-
tion of PTEN [29]. We therefore investigated whether ATF-2 was
involved in the inhibition of TM transcription. ATF-2, a member
of the ATF/CREB family of transcription factors, binds to the ATF/CREB site 50-TGACGTCA-30 and the AP-1 site 50-TGACTCA-30 [34].
The promoter region in the TM gene contains several putative
AP-1 half binding sites, including agTGACGgatt at 1288/1277,
gcTGACTcgct at 1026/1016, and ccTGACAgtgt at 939/929
(Fig. 3A). We ﬁrst examined whether ATF-2 can bind to the TM pro-
moter. Using the chromatin immunoprecipitation (ChIP) assay,
with an ATF-2 antibody for immunoprecipitation of the DNA–pro-
tein complex and subsequent PCR to detect associated DNA, we
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Fig. 3. Involvement of ATF-2 in PA-induced down-regulation of thrombomodulin expression. (A) Depiction of AP-1 sites in the TM promoter. (B) ATF-2 bound to TM promoter
and PA increased binding of ATF-2 to AP-1 sites in the TM promoter. HAECs were treated with PA for 24 h. Protein–DNA complex cross-linked by formaldehyde was
immunoprecipitated using anti-ATF-2 antibody, and speciﬁcally bound AP-1 sites were detected by PCR. (C) Involvement of ATF-2 in PA-induced down-regulation of
thrombomodulin mRNA. HAECs were transfected with negative control siRNA or ATF-2 siRNA and then treated with or without PA for 24 h. Relative TM mRNA was analyzed
by RT-PCR and normalized with b-actin mRNA. The relative levels of mRNA were compared and expressed as the percentage of the control. Data represent the mean ± S.E.M.
(N = 3). *P < 0.05, ***P < 0.001 versus PA with scrambled siRNA.
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gcTGACTcgct (1026/1016) and ccTGACAgtgt (939/929) sites
(Fig. 3B). Importantly, the binding was signiﬁcantly increased by
PA treatment, indicating that binding of ATF-2 to TM promoter
may be involved in PA-induced suppression of TM transcription.
Indeed, when HAECs cells were transiently transfected with ATF-
2-speciﬁc siRNAs before treated with PA, PA-induced inhibition
of TM expression was signiﬁcantly prevented (Fig. 3C). These data
support a critical role for ATF-2 transcription factor in PA-induced
down-regulation of TM transcription.
3.4. Recruitment of HDAC4 and formation of AFT-2/HDAC4
transcription repressor complex in the TM promoter
We ﬁnally investigated how the transcription factor ATF-2 can
bind to the TM promoter and inhibit gene expression; one possi-
ble mechanism is chromatin remodeling. Transcription factors
can bind to a promoter and form a transcription repressor com-
plex that recruits co-repressors such as HDACs, which deacetylate
histone, condense chromatin, and thereby inhibit gene transcrip-
tion. To test whether this mechanism applies in ATF-2-mediated
transcription repression of the TM gene, we ﬁrst identiﬁed HDACs
that can bind to the TM promoter. Using the ChIP assay, we found
that PA treatment signiﬁcantly increased HDAC4 binding to the
TM promoter (Fig. 4A). We then determined whether ATF-2 asso-
ciates with HDAC4 in vivo. Using a coimmunoprecipitation assay,
we observed that ATF-2 was associated with HDAC4 and that the
association was increased by PA treatment (Fig. 4B), indicating
that HDAC4 recruitment to the TM promoter may be mediated,
at least in part, by ATF-2. Finally, we used the double-chip assay
to determine if ATF-2 and HDAC4 were in the same transcription
repression complex in the TM promoter. The initial immunopre-
cipitation was conducted with an ATF-2 antibody, and the subse-
quent immunoprecipitation was done using the anti-HDAC4
antibody. The associated DNA in the immunocomplex was ampli-ﬁed by PCR. The double-chip assay (Fig. 4C) showed the TM pro-
moter sequence can be recovered from the immunocomplexes
precipitated by ATF-2 and HDAC4 antibodies, indicating the
simultaneous association of ATF-2 and HDAC4 within the region
of the TM promoter. Together, these results suggest that activated
ATF-2 may recruit HDAC4 and form a transcription repression
complex in the TM promoter.
4. Discussion
In the present study, we demonstrated that activated JNK and
p38 were involved in palmitic acid induced inhibition of TM
expression in HAECs. Their target transcription factor ATF-2 medi-
ated the inhibition. ATF-2 can bind and recruit HDAC4 to the TM
promoter, which may lead to histone deacetylation, chromatin
condensation and transcription arrest (Fig. 4D).
Thrombin-TM-protein C pathway is an important anticoagulant
system and TM is the key component in the system [6,14,35,36].
Downregulation of TM expression is associated with many throm-
botic and vascular conditions [6,14,35,36]. TM can be negatively
regulated by inﬂammatory factors [19–21] and oxidized lipids
[24–26]. In the present study, we demonstrated that TM expres-
sion can be inhibited by palmitic acid in HAECs, a mechanism that
may be implicated in the prothrombotic tendency in metabolic
syndrome.
We further investigated the mechanisms involved. JNK and p38
pathways can be activated by stress signals and contribute to many
pathological changes in cardiovascular diseases. Increasing evi-
dence suggest that activation of these pathways may also be
responsible for thrombosis dysregulation. It has been shown that
p38 and JNK are involved in platelet activation and aggregation
[37], upregulation of the expression of TF [38,39] and PAI-1
[40,41]. Recently, it has been shown that JNK and p38 mediated
TNFa induced down-regulation of TM expression [42]. Consistent
with this ﬁnding, our study demonstrated that JNK and p38
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856 Y. Rong et al. / FEBS Letters 584 (2010) 852–858pathways were also involved in fatty acid induced suppression of
TM expression. Thus, activation of JNK and p38 stress signaling
pathways may play signiﬁcant roles in the dysregulation of the
TM-protein C system and the coagulation–anticoagulation
imbalance.
How stress signaling down-regulates TM expression? ATF-2 is a
downstream target transcription factor of JNK and p38 pathways.
Previous study has reported that ATF-2 mediated LPS-induced TF
expression [43] and may be involved in thrombosis dysregulation.Recently, it has been shown that shear stress induces expression of
protective genes including TM, probably through inhibition of ATF-
2 [44]. In this study, we showed that ATF-2 mediated stress signal-
ing induced TM inhibition. ATF-2 bound to AP-1 binding sites in
the TM promoter and negatively regulated TM transcription, a pro-
cess that was enhanced by fatty acid treatment.
Furthermore, we examined how ATF-2 can bind to TM promoter
and suppress gene expression. The transcription switch of a given
gene is controlled by the coordinated activities of transcription
Y. Rong et al. / FEBS Letters 584 (2010) 852–858 857activator complexes and transcription repressor complexes. Tran-
scription repressor complexes recruit co-repressors such as HDACs,
which deacetylate histone, condense chromatin, and inhibit tran-
scription. In contrast, transcription activator complexes recruit
co-activators (i.e., CBP/p300), which acetylate histones, unwind
chromatin, and thereby promote transcription. Here we showed
that ATF-2 recruited HDAC4 and formed a transcription repressor
complexes on TM promoter, which may lead to histone deacetyla-
tion and subsequent transcription repression.
Nevertheless, other inhibitory mechanisms on TM transcription
may also exist. ATF-2 may inhibit transcription factors such as Sp-1
or coactivators such as CBP/p300, thus preventing the formation of
the functional transcription activator complex in the TM promoter.
Furthermore, TM can be controlled at different stages of its produc-
tion. Although our study leads us to hypothesize that down-regu-
lation of TM transcription may be an important mechanism for
decreased TM levels, FFAs may suppress TM protein expression
by reducing mRNA stability, inhibiting protein translation, or pro-
moting protein degradation through an ubiquitin-proteasome
pathway. Further studies will be necessary to deﬁne the detailed
mechanisms for the dysregulation of the TM-APC system by meta-
bolic stress and stress signaling pathways.
In summary, FFAs inhibit the expression of TM in HAECs. The
regulation is mediated by JNK and p38 pathways, which induce
the ATF-2/HDAC4 transcription repressor complex in the TM pro-
moter. This study provides novel insights into the molecular mech-
anisms of stress signaling-induced suppression of TM expression.
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